Mark Angelino

Mark joined TRV as a venture partner in 2021. He most recently served as Chief Operating Officer at Generation Bio (a non-viral, genetics medicine company), which he co-founded in 2016. From 2012 to 2016, Mark was on the leadership team at bluebird bio, as senior vice president of pharmaceutical sciences and rare disease franchise head. These two experiences combining novel therapeutic approaches and early builds is what drew Mark to Third Rock and its patient-centric mission.

Prior to that, at companies like Baxter Healthcare, Archemix, Millennium and DuPont Pharma, Mark acquired broad operational experience that cut across multiple modalities (small-molecules, ADCs, biologics, peptides, oligonucleotides, complex mixtures, and gene therapies), as well as across various stages of therapeutic development- from early translation to product launches. He also currently serves on the Board of Directors of Arbor Biotechnologies.